Drug Trial Radar · NCT04699669
A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Nov 27, 2018
Primary completion
Aug 20, 2019
Study completion Aug 20, 2019
Sponsor
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Phase 1 component of the study is a double-blind, placebo-controlled, single ascending dose (SAD) design intended to assess the safety, tolerability, and PK of CBL-514. The SAD part will involve 9 proposed dosing cohorts.
Conditions
- Subcutaneous Fat
Interventions
CBL-514, placeboDrug
One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume. Which side of the abdominal region to receive CBL-514 or placebo would be randomized. No PK samples will be collected in this cohort.
CBL-514, placeboDrug
One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume. Which side of the abdominal region to receive CBL-514 or placebo would be randomized.
CBL-514Drug
Both sides of the abdominal region will receive CBL-514.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse events (TEAEs)Time frame: Up to 4 weeks after treatment
- Number of participants with clinically significant abnormalities in clinical laboratory valuesTime frame: Up to 2 weeks after treatment
- Number of participants with clinically significant abnormalities in vital signsTime frame: Up to 2 weeks after treatment
- Number of participants with clinically significant abnormalities in Electrocardiogram (ECG)Time frame: Up to 2 weeks after treatment
- Number of participants with clinically significant abnormalities in physical examinationTime frame: Up to 2 weeks after treatment
- Number of participants with injection site reactionsTime frame: Up to 2 weeks after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational site
Melbourne, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.